Axonics, Inc. (AXNX)
| Market Cap | 3.63B |
| Revenue (ttm) | 431.90M +26.1% |
| Net Income | -5.66M |
| EPS | -0.11 |
| Shares Out | 51.11M |
| PE Ratio | n/a |
| Forward PE | 165.07 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 70.98 |
| Day's Range | 70.98 - 70.98 |
| 52-Week Range | 55.09 - 71.05 |
| Beta | 0.83 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 7, 2024 |
About AXNX
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to r... [Read more]
Financial Performance
In 2023, Axonics's revenue was $366.38 million, an increase of 33.86% compared to the previous year's $273.70 million. Losses were -$6.09 million, -89.80% less than in 2022.
Financial StatementsNews
Boston Scientific Closes Acquisition of Axonics, Inc.
MARLBOROUGH, Mass. , Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company ...
Axonics Reports Third Quarter 2024 Financial Results
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder a...
Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20® re...
Axonics Prevails in Patent Infringement Lawsuit with Medtronic
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic against Axonics in ...
Axonics Reports Second Quarter 2024 Financial Results
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder a...
Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15™ re...
Axonics Reports First Quarter 2024 Financial Results
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfu...
Boston Scientific Announces Results for First Quarter 2024
MARLBOROUGH, Mass. , April 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported...
FTC seeks more information on Boston Scientific's $3.7 bln Axonics deal
Boston Scientific said on Thursday the U.S. Federal Trade Commission (FTC) has requested additional information from the medical device maker related to its $3.7 billion deal to buy Axonics.
Axonics Stockholders Approve Merger Agreement with Boston Scientific
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt Axonics' merger agreement with Boston Scientific Corporation (NYSE: BSX). Accord...
Axonics Provides Update on Inter Partes Review Proceedings
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two ...
Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct...
Axonics Responds to ITC Action by Medtronic
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received notice that Medtronic has filed a complaint with the U.S. International Trade Commission (ITC), along...
Axonics Reports Fourth Quarter and Fiscal Year 2023 Financial Results
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct...
AXONICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Axonics, Inc. (N...
Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
MARLBOROUGH, Mass. , Jan. 31, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Axonics, Inc.
NEW YORK , Jan. 8, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Axonics, Inc. (NASDAQ: AXNX) and its board of directors concerning the proposed acquisit...
Axonics Stock Soars. It's Being Acquired By Boston Scientific In $3.7 Billion Deal.
The move will expand Boston's product portfolio in its urology business.
Boston Scientific To Acquire Axonics For About $3.7 Bln
Axonics had agreed to be bought for $71 a share. Boston Scientific said the deal gave Axonics an equity value of $3.7 billion and an enterprise value of $3.4 billion.
Boston Scientific to buy Axonics for $3.7 billion
Boston Scientific said on Monday it had agreed to buy medtech company Axonics Inc for $3.7 billion.
Boston Scientific Announces Agreement to Acquire Axonics, Inc.
Acquisition to expand urology portfolio with differentiated technologies to treat urinary and bowel dysfunction MARLBOROUGH, Mass. , Jan. 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: B...
Axonics Announces Definitive Agreement to be Acquired by Boston Scientific
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (NYSE: BSX) for $71 in cas...
Axonics Reports Preliminary 4Q23 and Fiscal Year 2023 Revenue
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct...
Axonics to Present at the J.P. Morgan Healthcare Conference
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct...
BiVACOR Appoints Veteran Medical Device Executive Raymond W. Cohen as Chairman of the Board of Directors
HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)--BiVACOR, Inc., a clinical-stage medical technology company developing a total artificial heart (TAH), today announced that Raymond W. Cohen has been appointe...